<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7e2f3780-88ee-4971-a4ab-3d6cd972c42c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Lincocin<sup>®</sup>
      </content>
      <br/>
      <content styleCode="bold"> lincomycin injection, USP</content>
   </title>
   <effectiveTime value="20250310"/>
   <setId root="c01906fa-2c73-4c13-9765-2fd06628d263"/>
   <versionNumber value="29"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
            <name>Pharmacia &amp; Upjohn Company LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
                        <name>Pharmacia &amp; Upjohn Company LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3cbaeea7-5afa-43da-9949-972cb75907fb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240607"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0009-0555" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lincocin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>lincomycin hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M6T05Z2B68" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LINCOMYCIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="BOD072YW0F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LINCOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="9.45"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-0555-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="19641229"/>
                                          <high value="20250630"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050317" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="19641229"/>
                              <high value="20250630"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38298" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCONJUNCTIVAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0009-0104" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lincocin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>lincomycin hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M6T05Z2B68" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LINCOMYCIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="BOD072YW0F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LINCOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="9.45"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-0104-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230818"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050317" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230818"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38298" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCONJUNCTIVAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0009-0107" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lincocin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>lincomycin hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M6T05Z2B68" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LINCOMYCIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="BOD072YW0F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LINCOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="9.45"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-0107-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230418"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050317" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230418"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38298" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCONJUNCTIVAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_34807600-8f45-40a0-9ef7-ec4ee3a2266f">
               <id root="2aa227c8-9b96-409f-af30-27e157d6936a"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Sterile Solution for Intramuscular and Intravenous Use</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of LINCOCIN and other antibacterial drugs, LINCOCIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="warningbox">
               <id root="cd596705-0f7c-4834-b231-f193b37d6693"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including LINCOCIN and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile.</content>
                  </paragraph>
                  <paragraph>Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the <content styleCode="bold">
                        <linkHtml href="#indications_usage">INDICATIONS AND USAGE</linkHtml>
                     </content> section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. </paragraph>
                  <paragraph>
                     <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                  <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
               </text>
               <effectiveTime value="20231106"/>
            </section>
         </component>
         <component>
            <section ID="ID_176200a5-fa16-4f9c-aef5-2789f21e55bf">
               <id root="959ef362-cefa-4919-a936-5d5fd7fd3fb5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>LINCOCIN (lincomycin injection, USP) is a sterile solution containing lincomycin hydrochloride which is the monohydrated salt of lincomycin, a lincosamide antibacterial produced by the growth of a member of the <content styleCode="italics">lincolnensis</content> group of <content styleCode="italics">Streptomyces lincolnensis</content> (Fam. <content styleCode="italics">Streptomycetaceae</content>). The chemical name for lincomycin hydrochloride is Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrolidinecarboxamido)-1-thio-D-erythro-α-D-galacto-octopyranoside monohydrochloride monohydrate. The molecular formula of lincomycin hydrochloride is C<sub>18</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>S.HCl.H<sub>2</sub>O and the molecular weight is 461.01.</paragraph>
                  <paragraph>The structural formula is represented below:</paragraph>
                  <renderMultiMedia ID="id517" referencedObject="MM1"/>
                  <paragraph>Lincomycin hydrochloride is a white or practically white, crystalline powder and is odorless or has a faint odor. Its solutions are acid and are dextrorotatory. Lincomycin hydrochloride is freely soluble in water; soluble in dimethylformamide and very slightly soluble in acetone.</paragraph>
                  <paragraph>LINCOCIN contains lincomycin hydrochloride in a sterile, clear, colorless solution with benzyl alcohol used as a preservative 9.45 mg/mL, and water for injection.</paragraph>
                  <paragraph>LINCOCIN is a sterile solution for intramuscular and intravenous use. LINCOCIN is supplied in 2 mL and 10 mL multiple-dose vials containing 300 mg/mL of lincomycin (equivalent to 340 mg/mL of lincomycin hydrochloride, USP).</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_feab0e77-6682-465a-a818-2babffdf4135">
               <id root="f708e650-a8b4-42a3-b2d0-20cfbf86e21d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Intramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum concentrations of 11.6 mcg/mL at 60 minutes and maintains therapeutic concentrations for 17 to 20 hours for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 17.3 percent).</paragraph>
                  <paragraph>A two hour intravenous infusion of 600 mg of lincomycin achieves average peak serum concentrations of 15.9 mcg/mL and maintains therapeutic concentrations for 14 hours for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent).</paragraph>
                  <paragraph>The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe renal impairment compared to patients with normal renal function. In patients with hepatic impairment, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum.</paragraph>
                  <paragraph>Tissue distribution studies indicate that bile is an important route of excretion. Significant concentrations have been demonstrated in most body tissues. Although lincomycin appears to diffuse into cerebrospinal fluid (CSF), concentrations of lincomycin in the CSF appear inadequate for the treatment of meningitis.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="microbiology">
                     <id root="f7596f7e-3420-4c1e-bad8-995992e50fc1"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <effectiveTime value="20230302"/>
                     <component>
                        <section ID="ID_bab95cea-9a3c-41ca-aa47-b9e00fd37488">
                           <id root="1ad70319-f932-42fa-94b8-f217618140e2"/>
                           <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                           <title>
                              <content styleCode="bold">Mechanism of Action</content>
                           </title>
                           <text>
                              <paragraph>Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic <content styleCode="italics">in vitro</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c21a2dcb-4554-4f6a-ad63-244ae62ce1cd">
                           <id root="279d4f70-d7f5-4d0b-87b5-535bb6d74247"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Resistance</content>
                           </title>
                           <text>
                              <paragraph>Cross resistance has been demonstrated between clindamycin and lincomycin. Resistance is most often due to methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit, which can determine cross resistance to macrolides and streptogramins B (MLS<sub>B</sub> phenotype). Macrolide-resistant isolates of these organisms should be tested for inducible resistance to lincomycin/clindamycin using the D-zone test or other appropriate method.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_6b6e6a4f-b8e4-4ba3-afbe-dbbec392778d">
                           <id root="6190088e-1652-4e4e-a927-45799a75202a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Antimicrobial Activity</content>
                           </title>
                           <text>
                              <paragraph>Lincomycin has been shown to be active against most strains of the following bacteria <content styleCode="bold">both <content styleCode="italics">in vitro</content> and in clinical infections:</content> (see <content styleCode="bold">
                                    <linkHtml href="#indications_usage">INDICATIONS AND USAGE</linkHtml>
                                 </content>).<br/>  <content styleCode="italics">Staphylococcus aureus</content>
                                 <br/>  <content styleCode="italics">Streptococcus pneumoniae</content>
                              </paragraph>
                              <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown.</paragraph>
                              <paragraph>Lincomycin has been shown to be active <content styleCode="italics">in vitro</content> against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials.</paragraph>
                              <paragraph>Gram-positive bacteria:<br/>  <content styleCode="italics">Corynebacterium diphtheriae</content>
                                 <br/>
                                 <content styleCode="italics">  Streptococcus pyogenes</content>
                                 <br/>  Viridans group streptococci</paragraph>
                              <paragraph>Anaerobic bacteria:<br/>  <content styleCode="italics">Clostridium tetani</content>
                                 <br/>  <content styleCode="italics">Clostridium perfringens</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1c4bb819-1ada-4b48-85eb-2d44f0ccb617">
                           <id root="4906e6b7-e7ff-4b00-ba47-32537239ce68"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Susceptibility Testing</content>
                           </title>
                           <text>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="indications_usage">
               <id root="6790e77e-900e-4811-aa9b-3932c6e613ee"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>LINCOCIN is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the <content styleCode="bold">
                        <linkHtml href="#warningbox">BOXED WARNING</linkHtml>
                     </content>, before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives.</paragraph>
                  <paragraph>Indicated surgical procedures should be performed in conjunction with antibacterial therapy.</paragraph>
                  <paragraph>LINCOCIN may be administered concomitantly with other antimicrobial agents when indicated.</paragraph>
                  <paragraph>LINCOCIN is not indicated in the treatment of minor bacterial infections or viral infections.</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of LINCOCIN and other antibacterial drugs, LINCOCIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="ID_44626310-6856-4252-a8e1-921117bd93ee">
               <id root="a87aadd7-7160-4bd1-a312-2718690ca27d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>LINCOCIN is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="warnings">
               <id root="9fa066e6-abd9-4568-b43b-96ffe0be0e7b"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>See <linkHtml href="#warningbox">BOXED WARNING</linkHtml>.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="ID_c638812e-ffc7-49e1-9ac5-57ff786258c3">
                     <id root="ad8063a7-6bb4-4a1c-b363-523f161c8755"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="italics">Clostridioides difficile</content> associated diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of  <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated. </paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_20018d3a-82c9-4676-9df2-30fbeebe3126">
                     <id root="eb082ad9-2fd8-4cc8-9d2f-5af03d70a876"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypersensitivity</title>
                     <text>
                        <paragraph>Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and erythema multiforme (EM) have been reported in patients receiving LINCOCIN therapy. If an anaphylactic reaction or severe skin reaction occurs, LINCOCIN should be discontinued and appropriate therapy should be initiated. (see <content styleCode="bold">
                              <linkHtml href="#adverse_reactions">ADVERSE REACTIONS</linkHtml>
                           </content>)</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04fa0572-962f-4232-a2ea-f024ff17ee1e">
                     <id root="40fd04f9-1a60-44e8-8d98-85763ebe7750"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Benzyl Alcohol Toxicity in Pediatric Patients (Gasping Syndrome)</title>
                     <text>
                        <paragraph>LINCOCIN contains benzyl alcohol as a preservative.</paragraph>
                        <paragraph>The preservative benzyl alcohol has been associated with serious adverse events, including the "gasping syndrome", and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_34100f9c-cca7-4a10-bd65-27542dc2cc4f">
                     <id root="62d04335-ce43-4df6-be9d-9b93bafd3e11"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Inadequate for Use in Meningitis</title>
                     <text>
                        <paragraph>Although lincomycin appears to diffuse into cerebrospinal fluid, concentrations of lincomycin in the CSF may be inadequate for the treatment of meningitis.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="PRECAUTIONS">
               <id root="4f62ae3c-3ec6-4fab-be43-b699b31cd966"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="ID_0960c5e7-480e-45de-8028-0e1963af3a82">
                     <id root="b4114a9a-fc9a-4c3a-bdb3-abde16118f24"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When LINCOCIN is indicated in these patients, they should be carefully monitored for change in bowel frequency.</paragraph>
                        <paragraph>LINCOCIN should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.</paragraph>
                        <paragraph>LINCOCIN should be used with caution in patients with a history of asthma or significant allergies.</paragraph>
                        <paragraph>Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibacterial therapy.</paragraph>
                        <paragraph>The use of LINCOCIN may result in overgrowth of nonsusceptible organisms, particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation. When patients with pre-existing <content styleCode="italics">Candida</content> infections require therapy with LINCOCIN, concomitant antifungal treatment should be given.</paragraph>
                        <paragraph>The serum half-life of lincomycin may be prolonged in patients with severe renal impairment compared to patients with normal renal function. In patients with hepatic impairment, serum half-life may be twofold longer than in patients with normal hepatic function.</paragraph>
                        <paragraph>Patients with severe renal impairment and/or hepatic impairment should be dosed with caution and serum lincomycin concentrations monitored during high-dose therapy. (see <content styleCode="bold">
                              <linkHtml href="#dosage_administration">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>)</paragraph>
                        <paragraph>Lincomycin MUST be diluted prior to intravenous infusion. For intravenous infusion, infuse over at least 60 minutes as directed in the <content styleCode="bold">
                              <linkHtml href="#dosage_administration">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content> Section. Do NOT administer as an intravenous bolus. Severe cardiopulmonary reactions have occurred at greater than the recommended concentration and rate.</paragraph>
                        <paragraph>Prescribing LINCOCIN in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5dd85724-18af-45bd-9c44-dc00c0357ef8">
                     <id root="67be2f83-2994-4c60-b96f-ed4ddde2c685"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be counseled that antibacterial drugs including LINCOCIN should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When LINCOCIN is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by LINCOCIN or other antibacterial drugs in the future.</paragraph>
                        <paragraph>Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with an antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after taking the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4e487dc7-0431-4c2d-89f0-b53ed6146853">
                     <id root="0925839e-95cb-4346-a08a-5b676fe49c34"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>During prolonged therapy with LINCOCIN, periodic liver and kidney function tests and blood counts should be performed.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_964ed3f7-c897-4a36-b834-d7cd3e4a7f0d">
                     <id root="1e732cde-f28c-4753-bd1b-47e31f2dd621"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e25c742c-1ac9-4543-adb9-d3bacba8495a">
                     <id root="07ee3a19-e010-4ad7-b883-8b4f25424eda"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>The carcinogenic potential of lincomycin has not been evaluated.</paragraph>
                        <paragraph>Lincomycin was not found to be mutagenic in the Ames <content styleCode="italics">Salmonella</content> reversion assay or the V79 Chinese hamster lung cells at the HGPRT locus. It did not induce DNA strand breaks in V79 Chinese hamster lung cells as measured by alkaline elution or chromosomal abnormalities in cultured human lymphocytes. <content styleCode="italics">In vivo</content>, lincomycin was negative in both the rat and mouse micronucleus assays and it did not induce sex-linked recessive lethal mutations in the offspring of male <content styleCode="italics">Drosophila</content>. However, lincomycin did cause unscheduled DNA syntheses in freshly isolated rat hepatocytes.</paragraph>
                        <paragraph>Impairment of fertility was not observed in male or female rats given oral 300 mg/kg doses of lincomycin (0.36 times the highest recommended human dose based on mg/m<sup>2</sup>).</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="PP">
                     <id root="36166a8d-893a-4f61-a149-23a7e401bf61"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women. LINCOCIN Sterile Solution contains benzyl alcohol as a preservative. Benzyl alcohol can cross the placenta. See<content styleCode="bold">
                              <linkHtml href="#warnings"> WARNINGS</linkHtml>
                           </content>. LINCOCIN should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                     <component>
                        <section ID="ID_08ed0d97-dbb1-4c02-924a-d0b95b4bd0e8">
                           <id root="f6cafab0-d707-4643-a784-e6997e4911a2"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>In a study with 60 pregnant women, cord serum concentrations were approximately 25% of the maternal serum concentrations, indicating that lincomycin crosses the placenta, and no substantial accumulation occurred in the amniotic fluid. Experience with 345 obstetrical patients receiving LINCOCIN revealed no ill effects related to pregnancy.</paragraph>
                              <paragraph>There was no evidence of teratogenicity when lincomycin was administered in diet to pregnant Sprague Dawley rats during the period of major organogenesis at doses up to 5000 mg/kg (approximately 6 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison).</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_8ab0b5cc-e6af-41d0-b0dc-7ff052d8b602">
                           <id root="2bb492c3-20a5-433a-b23e-3afd9233e15f"/>
                           <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Nonteratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>Reproduction studies performed in rats administered oral lincomycin in diet for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_b800db40-84f5-4b26-8ccf-210b1b4ac6a0">
                     <id root="e1d85443-7fb7-4a9c-b3d5-3dd2c4cd0ddd"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Lincomycin has been reported to appear in human milk in concentrations of 0.5 to 2.4 mcg/mL. Because of the potential for serious adverse reactions in nursing infants from LINCOCIN, a decision should be made whether to discontinue nursing, or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_83212127-8b81-4b4d-b40c-ab76890c9c33">
                     <id root="9db1877d-92d1-4ed0-8369-8472b0ba946a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>LINCOCIN contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "Gasping Syndrome" in premature infants. See<content styleCode="bold">
                              <linkHtml href="#warnings"> WARNINGS</linkHtml>
                           </content>. Safety and effectiveness in pediatric patients below the age of one month have not been established. (see <content styleCode="bold">
                              <linkHtml href="#dosage_administration">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>)</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="adverse_reactions">
               <id root="7aa819cc-2726-410a-a301-7b3080d6684f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been reported with the use of lincomycin.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="ID_555de553-1beb-4fa0-b53a-e516a01ac82e">
                     <id root="92a8b722-247c-428a-bbb9-291ed8fd7a46"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Gastrointestinal disorders</title>
                     <text>
                        <paragraph>Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort<footnote ID="_Ref724">Event has been reported with intravenous injection.</footnote>, anal pruritus</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f7dbcb48-6c04-4d46-a5c7-a30ecf7873f2">
                     <id root="55cbd300-9031-4421-84e1-9dac395a627c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Skin and subcutaneous tissue disorders</title>
                     <text>
                        <paragraph>Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, dermatitis bullous, dermatitis exfoliative, erythema multiforme (see <content styleCode="bold">
                              <linkHtml href="#warnings">WARNINGS</linkHtml>),</content> rash, urticaria, pruritus</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_566c39ac-cc19-403f-870f-b420da252e6b">
                     <id root="4a4ec4de-f355-4eb2-8709-9662a5b0c7e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Infections and infestations</title>
                     <text>
                        <paragraph>Vaginal infection, pseudomembranous colitis, <content styleCode="italics">Clostridioides difficile</content> colitis (see <content styleCode="bold">
                              <linkHtml href="#warnings">WARNINGS</linkHtml>
                           </content>)</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_11db82b9-7445-4dc4-a91e-e22f6b6095b1">
                     <id root="9ad96799-d93e-41c6-b7d2-fcfd2fe96d25"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Blood and lymphatic system disorders</title>
                     <text>
                        <paragraph>Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_73d60b86-e5b6-4e59-bb8a-07231a34df8b">
                     <id root="50d62b76-eb28-4bb7-89a4-ff2aaf1567f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Immune system disorders</title>
                     <text>
                        <paragraph>Anaphylactic reaction (see <content styleCode="bold">
                              <linkHtml href="#warnings">WARNINGS</linkHtml>
                           </content>), angioedema, serum sickness</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1e8c7118-ddef-45d3-957b-3d84d69cc8c5">
                     <id root="804a8698-31f0-4aa5-b8da-ccc48501a964"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hepatobiliary disorders</title>
                     <text>
                        <paragraph>Jaundice, liver function test abnormal, transaminases increased</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_37ec220d-c989-4ff3-9158-36b0d3f13eb7">
                     <id root="ad08fa73-103f-4a7b-9532-5de7e3a50639"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal and urinary disorders</title>
                     <text>
                        <paragraph>Renal impairment, oliguria, proteinuria, azotemia</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bf400473-2935-48ab-96a4-065bed33d54a">
                     <id root="f747c5cc-83b9-4233-b02d-2bcec92c7348"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cardiac disorders</title>
                     <text>
                        <paragraph>Cardio-respiratory arrest (see <content styleCode="bold">
                              <linkHtml href="#dosage_administration">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>)</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a1c93317-94e1-421f-be19-fa2cb12e45d9">
                     <id root="24d7dc2c-0587-4b85-a6eb-51a4aaf70c91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Vascular disorders</title>
                     <text>
                        <paragraph>Hypotension (see <content styleCode="bold">
                              <linkHtml href="#dosage_administration">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>), thrombophlebitis<footnoteRef IDREF="_Ref724"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_39902123-1d84-4221-ba5c-af8952168368">
                     <id root="6300fa7f-da34-460d-b15c-a5b8cb3b8d38"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Ear and labyrinth disorders</title>
                     <text>
                        <paragraph>Vertigo, tinnitus</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a11c1247-4976-45a8-b22e-554d0d25d9bf">
                     <id root="a3925fc2-047c-4d4a-b907-6e99a484aab6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Neurologic disorders</title>
                     <text>
                        <paragraph>Headache, dizziness, somnolence </paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_036af3bd-596a-42f7-b066-9797ad3d34a8">
                     <id root="27c11aea-c4ed-488c-a0de-bf7886a0f0e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>General disorders and administration site conditions</title>
                     <text>
                        <paragraph>Injection site abscess sterile<footnote ID="_Ref836">Reported with intramuscular injection.</footnote>, injection site induration<footnoteRef IDREF="_Ref836"/>, injection site pain<footnoteRef IDREF="_Ref836"/>, injection site irritation<footnoteRef IDREF="_Ref836"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_499b527f-c79b-4ae2-9fb9-b91220ae41f0">
               <id root="b7f74078-d4d6-41b7-bb14-56c3c27f78b2"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Serum concentrations of lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="dosage_administration">
               <id root="c5e5863b-f03f-4fac-a301-6a4cfdb083bd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>If significant diarrhea occurs during therapy, LINCOCIN should be discontinued. (see <content styleCode="bold">
                        <linkHtml href="#warningbox">BOXED WARNING</linkHtml>
                     </content>)</paragraph>
               </text>
               <effectiveTime value="20231106"/>
               <component>
                  <section ID="ID_e04d6f9a-95c9-48f3-9c61-1f405a234c20">
                     <id root="51a0a1e0-5acd-439d-a039-435466e66c86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>INTRAMUSCULAR</title>
                     <effectiveTime value="20230302"/>
                     <component>
                        <section ID="ID_e16e849c-c4d0-49f0-85c1-eb56898b72ab">
                           <id root="93618dc1-017d-4271-95d3-a208df9b8d0a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Adults</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Serious infections</content>—600 mg (2 mL) intramuscularly every 24 hours. <content styleCode="italics">More severe infections</content>—600 mg (2 mL) intramuscularly every 12 hours or more often.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_51a16d37-e0bf-4ea4-809f-9fbde259022a">
                           <id root="8cd6911e-20ec-47fb-8080-9fe6ad97cac0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Pediatric patients over 1 month of age</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Serious infections</content>—one intramuscular injection of 10 mg/kg (5 mg/lb) every 24 hours. <content styleCode="italics">More severe infections</content>—one intramuscular injection of 10 mg/kg (5 mg/lb) every 12 hours or more often.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_813fcd5f-c006-44dd-9c68-dd973055c550">
                     <id root="e1921d7e-23c9-4835-86f8-be96f4210591"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>INTRAVENOUS</title>
                     <effectiveTime value="20231106"/>
                     <component>
                        <section ID="ID_8c3394c9-fa1c-47be-9ace-5f6396df5719">
                           <id root="78b2ab44-4d33-4459-b9da-a89fafac2790"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Adults</content>
                           </title>
                           <text>
                              <paragraph>The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of lincomycin (2 mL of LINCOCIN) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. <content styleCode="bold">Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL of appropriate solution (see <linkHtml href="#physical_comp">PHYSICAL COMPATIBILITIES</linkHtml>) and infused over a period of not less than one hour.</content>
                              </paragraph>
                              <table width="60%">
                                 <col width="19%"/>
                                 <col width="21%"/>
                                 <col width="19%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" styleCode="Botrule Toprule " valign="top">
                                          <content styleCode="bold">Dose</content>
                                       </th>
                                       <th align="center" styleCode="Botrule Toprule " valign="top">
                                          <content styleCode="bold">Vol. Diluent</content>
                                       </th>
                                       <th align="center" styleCode="Botrule Toprule " valign="top">
                                          <content styleCode="bold">Time</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>600 mg</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>100 mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>1 hr</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top">
                                          <paragraph>1 gram</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>100 mL</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1 hr</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top">
                                          <paragraph>2 grams</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>200 mL</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>2 hr</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top">
                                          <paragraph>3 grams</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>300 mL</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3 hr</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>4 grams</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>400 mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>4 hr</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of lincomycin.</paragraph>
                           </text>
                           <effectiveTime value="20231106"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d3514937-4436-45a4-88c6-50f98fbdaf02">
                           <id root="294348bf-debe-4627-b257-301365273264"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Pediatric patients over 1 month of age</content>
                           </title>
                           <text>
                              <paragraph>10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection may be infused in divided doses as described above for adults.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">NOTE:</content> Severe cardiopulmonary reactions have occurred when LINCOCIN has been given at greater than the recommended concentration and rate (see <content styleCode="bold">
                                    <linkHtml href="#PRECAUTIONS">PRECAUTIONS</linkHtml>
                                 </content>).</paragraph>
                           </text>
                           <effectiveTime value="20231106"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_f9a64fcc-dc39-414a-8a91-6110e32edd95">
                     <id root="cb70b2e5-edcd-4a84-9134-f12fa30a300d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>SUBCONJUNCTIVAL INJECTION</title>
                     <text>
                        <paragraph>0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid concentrations of antibacterial (lasting for at least 5 hours) sufficient for most susceptible pathogens.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                     <component>
                        <section ID="ID_50943b8a-ae06-4978-b89f-2625a018b938">
                           <id root="9826e6dd-74f8-459a-abd2-5071827fb168"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Patients with Renal Impairment</content>
                           </title>
                           <text>
                              <paragraph>When therapy with LINCOCIN is required in individuals with severe renal impairment, an appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys (see <content styleCode="bold">
                                    <linkHtml href="#PRECAUTIONS">PRECAUTIONS</linkHtml>
                                 </content>).</paragraph>
                              <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                           </text>
                           <effectiveTime value="20230302"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_658437cd-d3ab-4426-8eba-4ca8515da818">
               <id root="62cbbde8-c291-45ab-8241-735c11efe864"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>LINCOCIN (lincomycin injection, USP) is available as a sterile, clear, and colorless solution in the following strength and package sizes:</paragraph>
                  <table width="65%">
                     <col width="33%"/>
                     <col width="31%"/>
                     <thead>
                        <tr>
                           <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                              <content styleCode="bold">Unit of Sale</content>
                           </th>
                           <th align="center" styleCode="Botrule Toprule " valign="top">
                              <content styleCode="bold">Concentration</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0009-0555-01 or NDC 0009-0104-04</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Toprule " valign="top">
                              <paragraph>600 mg/2 mL</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>2 mL multiple-dose vial</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="top">
                              <paragraph>(300 mg/mL)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0009-0107-04</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top">
                              <paragraph>3,000 mg/10 mL</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>10 mL multiple-dose vial</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="top">
                              <paragraph>(300 mg/mL)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Each mL of LINCOCIN contains 300 mg lincomycin (equivalent to 340 mg lincomycin hydrochloride, USP); also benzyl alcohol, 9.45 mg added as preservative.</paragraph>
               </text>
               <effectiveTime value="20231106"/>
               <component>
                  <section ID="ID_f9e0ae1c-da1e-42a0-9a5b-211c1355a98b">
                     <id root="3d5815ef-9893-4ba0-be9a-cfedf0540227"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_57b2d044-6818-4def-82e7-2489692e69f5">
               <id root="445374d0-8f7a-499b-a88c-a2b01e001a42"/>
               <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
               <title>ANIMAL PHARMACOLOGY</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">In vivo</content> experimental animal studies demonstrated the effectiveness of LINCOCIN preparations (lincomycin) in protecting animals infected with <content styleCode="italics">Streptococcus viridans,</content>β<content styleCode="italics">-hemolytic Streptococcus, Staphylococcus aureus, Streptococcus pneumoniae</content> and <content styleCode="italics">Leptospira pomona</content>. It was ineffective in <content styleCode="italics">Klebsiella, Pasteurella, Pseudomonas, Salmonella</content> and <content styleCode="italics">Shigella</content> infections.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="physical_comp">
               <id root="381e982d-305a-4e4b-ad1a-fcafd200d302"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>PHYSICAL COMPATIBILITIES</title>
               <text>
                  <paragraph>Physically compatible for 24 hours at room temperature unless otherwise indicated.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Infusion Solutions</content>
                     <br/>5% Dextrose Injection<br/>10% Dextrose Injection<br/>5% Dextrose and 0.9% Sodium Chloride Injection<br/>10% Dextrose and 0.9% Sodium Chloride Injection<br/>Ringer's Injection</paragraph>
                  <paragraph>
                     <sup>1</sup>/<sub>6</sub> M Sodium Lactate Injection<br/>Travert 10%-Electrolyte No. 1<br/>Dextran in Saline 6% w/v</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vitamins in Infusion Solutions</content>
                     <br/>B-Complex<br/>B-Complex with Ascorbic Acid</paragraph>
                  <paragraph>
                     <content styleCode="bold">Antibacterial in Infusion Solutions</content>
                     <br/>Penicillin G Sodium (Satisfactory for 4 hours)<br/>Cephalothin<br/>Tetracycline HCl<br/>Cephaloridine<br/>Colistimethate (Satisfactory for 4 hours)<br/>Ampicillin<br/>Methicillin<br/>Chloramphenicol<br/>Polymyxin B Sulfate</paragraph>
                  <paragraph>
                     <content styleCode="bold">Physically Incompatible with:</content>
                     <br/>Novobiocin<br/>Kanamycin</paragraph>
                  <paragraph>IT SHOULD BE EMPHASIZED THAT THE COMPATIBLE AND INCOMPATIBLE DETERMINATIONS ARE PHYSICAL OBSERVATIONS ONLY, NOT CHEMICAL DETERMINATIONS. ADEQUATE CLINICAL EVALUATION OF THE SAFETY AND EFFICACY OF THESE COMBINATIONS HAS NOT BEEN PERFORMED.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="ID_50f3b915-1c68-4384-bd7b-49f7c6198aba">
               <id root="1556d657-059e-441b-81d3-0e075a91eda1"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>For medical information about LINCOCIN, please visit <linkHtml href="http://www.pfizermedinfo.com">www.pfizermedinfo.com</linkHtml> or call 1-800-438-1985.</paragraph>
                  <renderMultiMedia ID="id1181" referencedObject="MM2"/>
                  <paragraph>LAB-0138-15.0<br/>Revised October 2023</paragraph>
               </text>
               <effectiveTime value="20231106"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_45478f9a-1f33-4cab-ba2d-51e6e1c56162">
               <id root="873e568f-e644-4b41-bab3-71026852b3bc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1-2 mL Vial Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pfizer</content>
                  </paragraph>
                  <paragraph>NDC 0009-0555-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lincocin</content>
                     <sup>®</sup>
                     <br/>lincomycin<br/>injection, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">300 mg/mL</content>
                  </paragraph>
                  <paragraph>1-2 mL Vial<br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <renderMultiMedia ID="id1211" referencedObject="MM3"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 1-2 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7cf261b0-53e1-4dba-ab45-bccedc5646a6">
               <id root="36f94c5b-1d04-4e72-b9dc-9136c7f36639"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton</title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0009-0555-01</paragraph>
                  <paragraph>Lincocin<sup>®</sup>
                     <br/>lincomycin<br/>injection, USP</paragraph>
                  <paragraph>300 mg/mL*</paragraph>
                  <paragraph>For intramuscular<br/>or intravenous use</paragraph>
                  <paragraph>1-2 mL Vial<br/>Rx only</paragraph>
                  <renderMultiMedia ID="id1236" referencedObject="MM4"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_095ad5ae-6a29-44b9-a0fe-b50d1ca1a210">
               <id root="62203ab7-6135-4739-8a95-9b6413e5e116"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mL Vial Label 0009-0104</title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0009-0104-04</paragraph>
                  <paragraph>Lincocin<sup>®</sup>
                     <br/>lincomycin injection, USP</paragraph>
                  <paragraph>600 mg/2 mL<br/>(300 mg/mL)</paragraph>
                  <paragraph>2 mL Multiple-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1258" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 2 mL Vial Label 0009-0104</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b1b96d4c-1264-4bcd-a4d7-ef0e39902396">
               <id root="ae59a52f-e03e-472d-a024-ab816d89fc38"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton 0009-0104</title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0009-0104-04</paragraph>
                  <paragraph>Lincocin<sup>®</sup>
                     <br/>lincomycin<br/>injection, USP</paragraph>
                  <paragraph>600 mg/2 mL<br/>(300 mg/mL)*</paragraph>
                  <paragraph>For intramuscular<br/>or intravenous use</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>One 2 mL Multiple-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1284" referencedObject="MM6"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton 0009-0104</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_18d79584-9281-4d54-83c0-6f002a22de73">
               <id root="10455f01-68d8-4c9b-afcd-72badb05dac1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mL Vial Label</title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0009-0107-04</paragraph>
                  <paragraph>Lincocin<sup>®</sup>
                     <br/>lincomycin injection, USP</paragraph>
                  <paragraph>3,000 mg/10 mL<br/>(300 mg/mL)*</paragraph>
                  <paragraph>For intramuscular or<br/>intravenous use</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>10 mL Multiple-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1309" referencedObject="MM7"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 10 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e7093565-ff89-4d6b-b1c6-443165716fdd">
               <id root="f0a07a79-0389-4912-80b4-77b0a7e56204"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0009-0107-04</paragraph>
                  <paragraph>Lincocin<sup>®</sup>
                     <br/>lincomycin<br/>injection, USP</paragraph>
                  <paragraph>3,000 mg/10 mL<br/>(300 mg/mL)*</paragraph>
                  <paragraph>For intramuscular<br/>or intravenous use</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>One 10 mL Multiple-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1335" referencedObject="MM8"/>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lincocin-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>